Martina Goetsch
About
Martina Goetsch is a scholar working on Genetics, Epidemiology and Hepatology.
According to data from OpenAlex, Martina Goetsch has authored 40 papers receiving a total of 296 indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Genetics, 19 papers in Epidemiology and 14 papers in Hepatology. Recurrent topics in Martina Goetsch's work include Inflammatory Bowel Disease (31 papers), Microscopic Colitis (18 papers) and Liver Diseases and Immunity (14 papers). Martina Goetsch is often cited by papers focused on Inflammatory Bowel Disease (31 papers), Microscopic Colitis (18 papers) and Liver Diseases and Immunity (14 papers). Martina Goetsch collaborates with scholars based in United States, Canada and Italy. Martina Goetsch's co-authors include Silvio Danese, Séverine Vermeire, William J. Sandborn, Andrés Yarur, Julián Panés, Geert D’Haens, Marla C. Dubinsky, Fabio Cataldi, Bruce E. Sands and Brian G. Feagan and has published in prestigious journals such as The Lancet, Gastroenterology and The American Journal of Gastroenterology.
In The Last Decade
Martina Goetsch
26 papers receiving 284 citations
Hit Papers
Peers
Martina Goetsch
Janelle Laskowski United States
Willem-Jan Wollants Belgium
B E Sands United States
Miloš Greguš United States
Jeff Hall United States
A. Parikh United States
Marcoli Cyrille United States
Nathalie Clerget–Chossat France
Róbert Sike Hungary
Eiichiro Noguchi Japan
Citations per year, relative to Martina Goetsch Martina Goetsch (= 1×)
peers
Janelle Laskowski
Countries citing papers authored by Martina Goetsch
Since
Specialization
Citations
This map shows the geographic impact of Martina Goetsch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Martina Goetsch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Martina Goetsch more than expected).
Fields of papers citing papers by Martina Goetsch
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Martina Goetsch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Martina Goetsch. The network helps show where Martina Goetsch may publish in the future.
Co-authorship network of co-authors of Martina Goetsch
This figure shows the co-authorship network connecting the top 25 collaborators of Martina Goetsch. A scholar is included among the top collaborators of Martina Goetsch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Martina Goetsch. Martina Goetsch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Vermeire, Séverine, David T. Rubin, Miguel Regueiro, et al.. (2025). DOP018 Etrasimod for the treatment of Ulcerative Colitis: Up to 4 years of safety data from the global clinical programme. Journal of Crohn s and Colitis. 19(Supplement_1). i119–i121.
2.
Sands, Bruce E., Marla C. Dubinsky, Paulo Gustavo Kotze, et al.. (2025). Efficacy and Safety of Etrasimod in Patients With Moderately to Severely Active Ulcerative Colitis Stratified by Baseline Modified Mayo Score: A Post Hoc Analysis From the Phase 3 ELEVATE UC Clinical Program. Inflammatory Bowel Diseases. 31(10). 2681–2692.
3.
Vermeire, Séverine, David T. Rubin, Laurent Peyrin-Biroulet, et al.. (2025). Cardiovascular events observed among patients in the etrasimod clinical programme: an integrated safety analysis of patients with moderately to severely active ulcerative colitis. BMJ Open Gastroenterology. 12(1). e001516–e001516.
4.
Feagan, B G, Maia Kayal, Stefan Schreiber, et al.. (2025). P1183 Multivariable analysis of baseline variables associated with efficacy outcomes in the ELEVATE UC clinical programme. Journal of Crohn s and Colitis. 19(Supplement_1). i2149–i2150.
5.
Vermeire, Séverine, Marla Dubinsky, Brian Feagan, et al.. (2024). P113 Maintenance of week 12 response through week 52 with etrasimod in patients with ulcerative colitis in ELEVATE UC 52. Poster presentations. A119.1–A119.
6.
Peyrin‐Biroulet, Laurent, Marla C. Dubinsky, Bruce E. Sands, et al.. (2024). Efficacy and Safety of Etrasimod in Patients with Moderately to Severely Active Isolated Proctitis: Results From the Phase 3 ELEVATE UC Clinical Programme. Journal of Crohn s and Colitis. 18(8). 1270–1282.
7.
Vermeire, Séverine, Bruce E. Sands, Laurent Peyrin‐Biroulet, et al.. (2024). Impact of Prior Biologic or Janus Kinase Inhibitor Therapy on Efficacy and Safety of Etrasimod in the ELEVATE UC 52 and ELEVATE UC 12 Trials. Journal of Crohn s and Colitis. 18(11). 1780–1794.
8.
Armuzzi, Alessandro, David T. Rubin, S Schreiber, et al.. (2024). Health-Related Quality of Life Outcomes With Etrasimod Treatment in Patients With Ulcerative Colitis: A Post Hoc Analysis of Data From ELEVATE UC 52 and ELEVATE UC 12. Inflammatory Bowel Diseases. 31(6). 1583–1594.
9.
Sands, Bruce E., Yvette Leung, David T. Rubin, et al.. (2024). Etrasimod Corticosteroid-Free Efficacy, Impact of Concomitant Corticosteroids on Efficacy and Safety, and Corticosteroid-Sparing Effect in Ulcerative Colitis: Analyses of the ELEVATE UC Clinical Program. Journal of Crohn s and Colitis. 19(3).
10.
Regueiro, Miguel, Britta Siegmund, Andrés Yarur, et al.. (2024). Etrasimod for the Treatment of Ulcerative Colitis: Analysis of Infection Events from the ELEVATE UC Clinical Programme. Journal of Crohn s and Colitis. 18(10). 1596–1605.
11.
Yarur, Andrés, Michael Chiorean, Jessica R. Allegretti, et al.. (2024). Etrasimod as a Monotherapy or With Concomitant Use of Corticosteroids and/or Aminosalicylates: Results From the ELEVATE UC Clinical Program. Inflammatory Bowel Diseases. 31(8). 2144–2153.
12.
Lees, Charlie W., Joana Torres, Yvette Leung, et al.. (2024). P540 Non-serious adverse events in patients with ulcerative colitis receiving etrasimod: An analysis of the phase 2 OASIS and phase 3 ELEVATE UC 52 and ELEVATE UC 12 clinical trials. Journal of Crohn s and Colitis. 18(Supplement_1). i1055–i1057.
13.
Siegmund, Britta, Catherine M. Crosby, Séverine Vermeire, et al.. (2024). S1137 The Impact of Etrasimod on the Transcriptome in Colon Biopsies Using RNA-Seq: Data from ELEVATE UC 52 and ELEVATE UC 12 Phase 3 Clinical Trials. The American Journal of Gastroenterology. 119(10S). S808–S808.
14.
Lees, Charlie W., Joana Torres, Yvette Leung, et al.. (2024). Non-serious adverse events in patients with ulcerative colitis receiving etrasimod: an analysis of the phase II OASIS and phase III ELEVATE UC 52 and ELEVATE UC 12 clinical trials. Therapeutic Advances in Gastroenterology. 17. 1118476619–1118476619.
15.
Magro, Fernando, Laurent Peyrin‐Biroulet, Bruce E. Sands, et al.. (2024). Endoscopic, Histologic, and Composite Endpoints in Patients With Ulcerative Colitis Treated With Etrasimod. Clinical Gastroenterology and Hepatology. 23(2). 341–350.e6.
16.
Vermeire, Séverine, Silvio Danese, William J. Sandborn, et al.. (2023). Efficacy and Safety of the Anti-mucosal Addressin Cell Adhesion Molecule-1 Antibody Ontamalimab in Patients with Moderate-to-Severe Ulcerative Colitis or Crohn’s Disease. Journal of Crohn s and Colitis. 18(5). 708–719.
17.
Sandborn, William J., Séverine Vermeire, Laurent Peyrin‐Biroulet, et al.. (2023). Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies. The Lancet. 401(10383). 1159–1171.
18.
Vermeire, Séverine, David T. Rubin, Laurent Peyrin‐Biroulet, et al.. (2023). S905 Impact of Etrasimod on Blood Pressure and Hypertension: Data From the Etrasimod Ulcerative Colitis Clinical Program. The American Journal of Gastroenterology. 118(10S). S675–S675.
19.
Siegmund, Britta, H. Kiyomi Komori, María T. Abreu, et al.. (2023). Tu1724 EFFECT OF ETRASIMOD ON IMMUNE CELL SUBSETS IN COLONIC TISSUE OF PATIENTS WITH ULCERATIVE COLITIS: IMMUNOPHENOTYPING ANALYSIS OF COLON BIOPSY SAMPLES FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS. Gastroenterology. 164(6). S–1095.
20.
Reinisch, Walter, William J. Sandborn, Silvio Danese, et al.. (2019). DOP51 Biomarker and pharmacokinetic data from the TURANDOT II open-label extension study of the anti-mucosal addressin cell adhesion molecule-1 (MAdCAM-1) antibody SHP647 in patients with ulcerative colitis. Journal of Crohn s and Colitis. 13(Supplement_1). S058–S059.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Janelle Laskowski Breakdown of academic impact, for papers by Willem-Jan Wollants Breakdown of academic impact, for papers by B E Sands Breakdown of academic impact, for papers by Miloš Greguš Breakdown of academic impact, for papers by Jeff Hall Breakdown of academic impact, for papers by A. Parikh Breakdown of academic impact, for papers by Marcoli Cyrille Breakdown of academic impact, for papers by Nathalie Clerget–Chossat Breakdown of academic impact, for papers by Róbert Sike Breakdown of academic impact, for papers by Eiichiro Noguchi